Contrasting DLocal (NASDAQ:DLO) and Hyperion DeFi (NASDAQ:HYPD)
by Kim Johansen · The Markets DailyDLocal (NASDAQ:DLO – Get Free Report) and Hyperion DeFi (NASDAQ:HYPD – Get Free Report) are both finance companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Risk and Volatility
DLocal has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for DLocal and Hyperion DeFi, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DLocal | 0 | 1 | 6 | 0 | 2.86 |
| Hyperion DeFi | 2 | 0 | 2 | 0 | 2.00 |
DLocal presently has a consensus price target of $18.83, indicating a potential upside of 28.47%. Hyperion DeFi has a consensus price target of $7.77, indicating a potential upside of 111.85%. Given Hyperion DeFi’s higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than DLocal.
Institutional & Insider Ownership
90.1% of DLocal shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 45.4% of DLocal shares are owned by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares DLocal and Hyperion DeFi”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DLocal | $1.09 billion | 3.95 | $196.80 million | $0.67 | 21.88 |
| Hyperion DeFi | $810,000.00 | 70.41 | -$45.31 million | ($6.53) | -0.56 |
DLocal has higher revenue and earnings than Hyperion DeFi. Hyperion DeFi is trading at a lower price-to-earnings ratio than DLocal, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DLocal and Hyperion DeFi’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DLocal | 15.04% | 41.64% | 12.96% |
| Hyperion DeFi | 416.56% | -11.62% | -9.96% |
Summary
DLocal beats Hyperion DeFi on 10 of the 14 factors compared between the two stocks.
About DLocal
DLocal Limited operates a payment processing platform worldwide. The company offers pay-in solution which the business and get paid for their products and services through various payment methods, including international and local cards, online bank transfers and direct debit, cash, and alternative payment methods. It also provides pay-out solution used for merchants to scale pay-out operations. In addition, the company offers dLocal for Platforms, an end-to-end payment solution that offers a range of services to help platforms manage payments. It serves its products to commerce, streaming, ride-hailing, financial services, advertising, SaaS, travel, e-learning, on-demand delivery, and gaming and crypto industries. DLocal Limited was founded in 2016 and is headquartered in Montevideo, Uruguay.
About Hyperion DeFi
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.